r d systems co Search Results


h1915  (R&D Systems)
93
R&D Systems h1915
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
H1915, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h1915/product/R&D Systems
Average 93 stars, based on 1 article reviews
h1915 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
poly l lysine  (R&D Systems)
93
R&D Systems poly l lysine
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Poly L Lysine, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/poly l lysine/product/R&D Systems
Average 93 stars, based on 1 article reviews
poly l lysine - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant rat platelet  (R&D Systems)
92
R&D Systems recombinant rat platelet
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Recombinant Rat Platelet, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant rat platelet/product/R&D Systems
Average 92 stars, based on 1 article reviews
recombinant rat platelet - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
recombinant human il 6  (R&D Systems)
96
R&D Systems recombinant human il 6
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Recombinant Human Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 6/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant human il 6 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
color reagent b tetramethylbenzidine  (R&D Systems)
95
R&D Systems color reagent b tetramethylbenzidine
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Color Reagent B Tetramethylbenzidine, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/color reagent b tetramethylbenzidine/product/R&D Systems
Average 95 stars, based on 1 article reviews
color reagent b tetramethylbenzidine - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
recombinant mouse il  (R&D Systems)
96
R&D Systems recombinant mouse il
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Recombinant Mouse Il, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse il/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant mouse il - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
recombinant glial cell line  (R&D Systems)
96
R&D Systems recombinant glial cell line
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Recombinant Glial Cell Line, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant glial cell line/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant glial cell line - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
akr1c1  (R&D Systems)
91
R&D Systems akr1c1
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Akr1c1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/akr1c1/product/R&D Systems
Average 91 stars, based on 1 article reviews
akr1c1 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
goat anti mouse mbl a  (R&D Systems)
88
R&D Systems goat anti mouse mbl a
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Goat Anti Mouse Mbl A, supplied by R&D Systems, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti mouse mbl a/product/R&D Systems
Average 88 stars, based on 1 article reviews
goat anti mouse mbl a - by Bioz Stars, 2026-03
88/100 stars
  Buy from Supplier
detection antibodies haec adhesion molecule chemokine antibody cx3cli1 pe mouse anti hcx3cl1 r  (R&D Systems)
91
R&D Systems detection antibodies haec adhesion molecule chemokine antibody cx3cli1 pe mouse anti hcx3cl1 r
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Detection Antibodies Haec Adhesion Molecule Chemokine Antibody Cx3cli1 Pe Mouse Anti Hcx3cl1 R, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/detection antibodies haec adhesion molecule chemokine antibody cx3cli1 pe mouse anti hcx3cl1 r/product/R&D Systems
Average 91 stars, based on 1 article reviews
detection antibodies haec adhesion molecule chemokine antibody cx3cli1 pe mouse anti hcx3cl1 r - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
human proteome profiler protease array  (R&D Systems)
93
R&D Systems human proteome profiler protease array
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Human Proteome Profiler Protease Array, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human proteome profiler protease array/product/R&D Systems
Average 93 stars, based on 1 article reviews
human proteome profiler protease array - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
endothelial cells  (R&D Systems)
96
R&D Systems endothelial cells
YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts <t>H1915</t> (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.
Endothelial Cells, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/endothelial cells/product/R&D Systems
Average 96 stars, based on 1 article reviews
endothelial cells - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts H1915 (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.

Journal: bioRxiv

Article Title: YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

doi: 10.1101/2023.12.19.572449

Figure Lengend Snippet: YAP1 status does not predict sensitivity to cisplatin in LCNEC cell lines (A) or cell line/PDX xenograft models (B). C, Treatment of LCNEC cell lines with DMSO, cisplatin, MYF-01-37, XAV-939 and decitabine did not change YAP1, but verteporfin reduced YAP1 levels. D, YAP1 status does not predict response to verteporfin. E, Waterfall plot of drug sensitivity in LCNEC cell lines. A comparison of high YAP1 levels and IC50 values identified several drugs with similar targets, including MEK1/2, CDK4/6, and Src family kinase inhibitors. F, Treatment of YAP1-high LCNEC and SCLC (SW1271) cell lines with trametinib did not change YAP1 levels. G, Tumor growth curves from YAP1-high cell line xenografts H1915 (LCNEC) and SW1271 (SCLC) demonstrate a delay in tumor growth with trametinib treatment.

Article Snippet: One million cells each for H810, H1155, H1755, H1833, H2106, MKL1, HCC2374, HCC4017, HOP92, H1359, H2066, H1770, H2106, H1570, H661, HCC3051, H460, HCC4017, H1299, and H1915 in triplicate were surfaced stained with DLL3 (FAB4315P; R&D Systems), AXL (386202; Biolegends), CD56 (362534), EPCAM (324222) or IgG control and then fixed in 2% PFA.

Techniques: Comparison